There are meta-analyses of glucose-lowering drugs that support the evidence of potential stroke-protective effects from treatment with pioglitazone and GLP-1R15,16, whereas dipeptidyl peptidase-4 (DPP-4) inhibitors have a neutral effect against stroke17. This evidence concerns the gene DPP4 and stroke disorder.